Anti-ZIP7/SLC39A7 monoclonal antibody
The Alternative Names of target: AGM9,D6S115E,D6S2244E,H-2Ke4,H2-KE4,H2-Ke4,HKE4,Histidine-rich membrane protein Ke4,Irt-like protein 7 (ZIP7),KE4,Ke-4,Ke4,RING5,RT1-Ke4,Really interesting new gene 5 protein,Ring5,Rt1Ke4,SLC39A7,Slc39a7,Solute carrier family 39 member 7,ZIP7,Zinc transporter SLC39A7,Zip7,Zrt-,ke4
Pre-made anti-ZIP7/SLC39A7 monoclonal antibody (mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.
Go
to ZIP7/SLC39A7 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1738-Ab-1/ GM-Tg-hg-IP1738-Ab-2 | Anti-Human ZIP7/SLC39A7 monoclonal antibody | Human |
GM-Tg-rg-IP1738-Ab-1/ GM-Tg-rg-IP1738-Ab-2 | Anti-Rat ZIP7/SLC39A7 monoclonal antibody | Rat |
GM-Tg-mg-IP1738-Ab-1/ GM-Tg-mg-IP1738-Ab-2 | Anti-Mouse ZIP7/SLC39A7 monoclonal antibody | Mouse |
GM-Tg-cynog-IP1738-Ab-1/ GM-Tg-cynog-IP1738-Ab-2 | Anti-Cynomolgus/Rhesus macaque ZIP7/SLC39A7 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1738-Ab-1/ GM-Tg-felg-IP1738-Ab-2 | Anti-Feline ZIP7/SLC39A7 monoclonal antibody | Feline |
GM-Tg-cang-IP1738-Ab-1/ GM-Tg-cang-IP1738-Ab-2 | Anti-Canine ZIP7/SLC39A7 monoclonal antibody | Canine |
GM-Tg-bovg-IP1738-Ab-1/ GM-Tg-bovg-IP1738-Ab-2 | Anti-Bovine ZIP7/SLC39A7 monoclonal antibody | Bovine |
GM-Tg-equg-IP1738-Ab-1/ GM-Tg-equg-IP1738-Ab-2 | Anti-Equine ZIP7/SLC39A7 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. |
GM-Tg-hg-IP1738-Ab-1/ GM-Tg-hg-IP1738-Ab-2;
GM-Tg-rg-IP1738-Ab-1/ GM-Tg-rg-IP1738-Ab-2;
GM-Tg-mg-IP1738-Ab-1/ GM-Tg-mg-IP1738-Ab-2; GM-Tg-cynog-IP1738-Ab-1/ GM-Tg-cynog-IP1738-Ab-2; GM-Tg-felg-IP1738-Ab-1/ GM-Tg-felg-IP1738-Ab-2; GM-Tg-cang-IP1738-Ab-1/ GM-Tg-cang-IP1738-Ab-2; GM-Tg-bovg-IP1738-Ab-1/ GM-Tg-bovg-IP1738-Ab-2; GM-Tg-equg-IP1738-Ab-1/ GM-Tg-equg-IP1738-Ab-2 |
Products Name | Anti-ZIP7/SLC39A7 monoclonal antibody |
Format | mab |
Target Name | ZIP7/SLC39A7 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) |
IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-ZIP7/SLC39A7 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.